The future of pharmacological therapy for heart failure

Circulation Journal

Volumn 74, Issue 5, 2010, Pages 809-817

  Sata, Yusuke ^a   Krum, Henry ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cardiac function; Heart failure; Pharmacology

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUCINDOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; ERYTHROPOIETIN; ETANERCEPT; FUROSEMIDE; GLYCERYL TRINITRATE; INFLIXIMAB; LOSARTAN; MILRINONE; NAXIFYLLINE; NESIRITIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMAPATRILAT; PERINDOPRIL; PLACEBO; RENIN INHIBITOR; ROLOFYLLINE; SPIRONOLACTONE; TOLVAPTAN; UNINDEXED DRUG; URODILATIN;

ACUTE HEART FAILURE; ADRENERGIC SYSTEM; ANEMIA; CARDIORENAL ANEMIA SYNDROME; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC HEART FAILURE;

ALDOSTERONE; ANGIOTENSINS; DRUG THERAPY; HEART FAILURE; HUMANS; RENIN;

EID: 77951747397     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0272     Document Type: Review

References (63)

1. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: The cytokine hypothesis. J Card Fail 1996; 2: 243-249.
2. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001; 6: 71-80.
3. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86: 123-130.
4. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endo-thelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195-197.
5. Pastelín Hernández G, del Valle Mondragón L, Tenorio López FA. From basic research to clinical results: The OVERTURE, ENABLE, and RENEWAL studies. Arch Cardiol Mex 2003; 73(Suppl 1): S112-S115 (in Spanish).
6. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): Approaching the asymptote of efficacy? J Card Fail 2002; 8: 124-127.
7. Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials update: Highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLEICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002; 4: 381-388.
8. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926.
9. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
10. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260-269.
11. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
12. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001; 37: 1808-1812.
13. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA, et al. Pharmacogenetic interactions between betablocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103: 1644-1648.
14. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1) adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006; 103: 11288-11293.
15. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
16. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. Acute heart failure syndromes: Current state and framework for future research. Circulation 2005; 112: 3958-3968.
17. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184-3189.
18. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure: Nesiritide Study Group. N Engl J Med 2000; 343: 246-253.
19. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 2002; 90: 435-438.
20. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtal TH, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57-64.
21. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 2002; 287: 1541-1547.
22. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003.
23. Felker GM, O'Connor CM. Inotropic therapy for heart failure: An evidence-based approach. Am Heart J 2001; 142: 393-401.
24. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007; 153: 98-104.
25. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002; 287: 1531-1540. Erratum in: JAMA 2002; 288: 577.
26. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008; 118: 2259-2267.
27. Miyagishima K, Hiramitsu S, Kimura H, Mori K, Ueda T, Kato S, et al. Long term prognosis of chronic heart failure: Reduced vs preserved left ventricular ejection fraction. Circ J 2009; 73: 92-99.
28. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
29. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
30. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
31. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999; 341: 753-755.
32. http://clinicaltrial.gov/ct2/show/NCT00232180 (accessed 5 April, 2010).
33. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701.
34. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: A comparison with spironolactone. Eur Heart J 2008; 29: 2171-2179.
35. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 2006; 296: 1465-1466.
36. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
37. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-1353.
38. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, et al. The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008; 14: 631-640.
39. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009; 14: 321-329.
40. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439.
41. Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: A doubleblind, placebo-controlled, ascending-dose trial. Am Heart J 2005; 150: 1239.
42. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 2009; 14: 309-319.
43. Nishikimi T, Karasawa T, Inaba C, Ishimura K, Tadokoro K, Koshikawa S, et al. Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: A pilot study. Circ J 2009; 73: 892-898.
44. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijingaarden J, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008; 29: 1510-1515.
45. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): A Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009; 11: 795-801.
46. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIRHF) study: A randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009; 11: 1084-1091.
47. Lipsic E, van der Meer P. Erythropoietin, iron, or both in heart failure: FAIR-HF in perspective. Eur J Heart Fail 2010; 12: 104-105.
48. Anand IS, Liu D, Chugh SS, Prahash AJ, Gupta S, John R, et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 1997; 96: 3974-3984.
49. Chen C, Ma L, Dyckman W, Santos F, Lai T, Gillam LD, et al. Left ventricular remodeling in myocardial hibernation. Circulation 1997; 96(Suppl): II-46-II-50.
50. Sundstrom J, Lind L, Nystrom N, Zethelius B, Andren B, Hales CN, et al. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 2000; 101: 2595-2600.
51. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
52. Ghali JK, Smith WB, Torre-Amione G, Haynos W, Rayburn BK, Amato A, et al. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 2007; 99: 47A-56A.
53. Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 2009; 157: 1035-1041.
54. See F, Kompa A, Martin J, Lewis DA, Krum H. Fibrosis as a therapeutic target post-myocardial infarction. Curr Pharm Des 2005; 11: 477-487.
55. Lee KW, Everett TH 4th, Rahmutula D, Guerra JM, Wilson E, Ding C, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114: 1703-1712.
56. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657-687.
57. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002; 106: 1243-1250.
58. Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, Krum H, et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2007; 293: H2860-H2869.
59. Zammit SC, Cox AJ, Gow RM, Zhang Y, Gilbert RE, Krum H, et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009; 19: 7003-7006.
60. Palatini P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: The effect of antihypertensive drugs. Drugs 1999; 57: 713-724.
61. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974.
62. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: Findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-1334.
63. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.